The Chinese Academy of Sciences and Weigao Group jointly issued the first batch of high-tech research program support projects
Business Club April 25th National medical device companies are looking for the dilemma of foreign companies monopolizing the high-end market.
On April 23, Shandong Weigao Group, the leading medical device company in China, and the Chinese Academy of Sciences jointly released the first batch of high-tech research project support projects. The first guideline project application reached 122 items. After careful discussions with the leading group, the current guideline was planned. 8 funded projects, involving titanium alloys for orthopaedic and implantable devices, polymer materials for blood transfusion, storage, and purification, bioinorganic materials for coating of orthopedic implants, and spinal cord Rehabilitation robots for injury and controlled release agents for tumor drugs.
On the same day, the two parties also jointly issued the second China Academy of Sciences-WeiGao Group's second scientific research project guide. The main R&D directions include high-tech fields such as medical materials, medical consumables, medical equipment, and biomedicine.
“Current domestic hospitals use high-end medical consumables, diagnostic and therapeutic equipment, and implanted therapeutic devices and devices, which mainly rely on imports. This is one of the main factors contributing to high domestic treatment costs.†Chen Xueli, chairman of Weigao Group’s Board of Directors, told the reporter. The Weigao Group has researched and developed the above materials and machinery. After mass production, the cost of domestic products will be reduced by 50-60%."
In the investigation, the reporter found that the overall technology of China's medical devices is far from the advanced level in foreign countries. In some high-end product areas, foreign companies are in an absolute monopoly position.
“High-end medical devices such as electrocardiographs, CTs, magnetic resonances, etc. can hardly see domestic brands, and multinational companies have monopolized more than 80% of the domestic market share.†Zheng Quanlu, former vice president of the China Medical Device Industry Association, told reporters in the field of ultrasonic instruments and magnetics. In areas such as resonance equipment, the monopoly share of multinational corporations even exceeds 90%. “This is a de facto absolute monopoly. The result is a high price, and it also exacerbates the problem of the 'expensive' doctors.â€
According to statistics from the China Medical Device Industry Association, there are about 3,000 medical device manufacturers in China, but most of them are small in scale and have limited market power. Most of the high-end medical devices are based on imitation and improvement, with the exception of individual companies. .
“If we only focus on the medium and low-end markets, the path for Chinese medical device companies will only go further and narrower.†Chen Xueli said that the localization of high-end medical devices not only helps improve the overall competitiveness of China's medical devices, but also can effectively reduce the people. Medical costs.
In 2005, Weigao Group and the Dalian Institute of Chemicals of the Chinese Academy of Sciences jointly developed a recombinant protein immunoadsorption column, which was mainly used for the rejection reaction caused by hemodialysis or organ transplantation to break the monopoly of the German Fresenius company.
Previously, domestic hemodialysis patients needed more than RMB 400 per dialysis fee, and each patient needed more than RMB 60,000 per year; after WeiGao achieved localization, the cost per dialysis could drop by nearly 50%, and it could be for each year. The patient saves more than 30,000 yuan, while there are more than 2 million patients with kidney disease in China. If we use Weigao's products for treatment, it can save more than 60 billion yuan per year for kidney dialysis patients nationwide.
In recent years, the medical device industry in China has developed rapidly. However, the medical device industry is a comprehensive industry with a high concentration of technologies and involves a wide range of disciplines. The technical threshold is high. Based on the late start, the technology of the Chinese medical industry is far below the international level. To this end, the Chinese Academy of Sciences has increased the research and layout of medical devices, medical materials, and Pratt & Whitney's low-cost medical treatment methods, and has made a number of important scientific and technological achievements.
To promote the development of domestic medical equipment, medical devices, medical materials and biopharmaceutical industries, research and development of disease diagnosis and treatment methods and products with high technical level, good product quality, and cost-effective products, April 29, 2010, Chinese Academy of Sciences and Weigao Group The framework agreement for the "Chinese Academy of Sciences - Weigao Group High-Tech Research and Development Program" was signed.
According to the agreement, the development plan will annually arrange R&D expenses of 30 million yuan, of which Weigao Group will invest 15 million yuan, Shandong Province Science and Technology Agency will invest 5 million yuan on behalf of Shandong Province, Chinese Academy of Sciences will invest 5 million yuan, and the Weihai Municipal Government will invest 5 million yuan. All funds are mainly invested in the frontiers of scientific and technological development in China's medical equipment, medical equipment, medical materials, and bio-pharmaceuticals, and strive to integrate superior resources of the domestic medical device industry in basic theoretical research, applied technology research and development, product trial production, innovation platform construction, and information We will carry out all-round cooperation with personnel exchanges and other areas to jointly improve the ability of independent innovation and the market competitiveness of enterprises.
The leader of the cooperation program and head of the Shenyang Branch of the Chinese Academy of Sciences, Bao Xinhe, said: "The establishment of this plan is a new attempt by the Chinese Academy of Sciences to explore cooperation models with government and private enterprises, and promote the effective integration of science and technology with the economy and promote The scientific and technological system reform and other aspects are important examples. The successful implementation of the plan will further strengthen the promotion of research results of the Chinese Academy of Sciences and promote the rapid development of high-end medical devices and important biomedical materials in China."
"In addition to localization of high-end medical devices, we can break the monopoly of foreign companies to the market, and will also solve the problem of 'expensive medical services' to some extent." Zheng Quanlu said that foreign companies such as Medtronic, BD and Johnson & Johnson have monopolized more than 80% of domestic high-end products. The medical device market has led to high prices, and scientific research institutions need to increase support for ethnic medical device companies.
"National medical devices should go out of the competition of homogenization, accelerate independent innovation and industrial upgrading, vigorously develop high-end products, and form their own iconic products, core competitiveness and international brands," said Chen Xueli.
Business Club April 25th National medical device companies are looking for the dilemma of foreign companies monopolizing the high-end market.
On April 23, Shandong Weigao Group, the leading medical device company in China, and the Chinese Academy of Sciences jointly released the first batch of high-tech research project support projects. The first guideline project application reached 122 items. After careful discussions with the leading group, the current guideline was planned. 8 funded projects, involving titanium alloys for orthopaedic and implantable devices, polymer materials for blood transfusion, storage, and purification, bioinorganic materials for coating of orthopedic implants, and spinal cord Rehabilitation robots for injury and controlled release agents for tumor drugs.
On the same day, the two parties also jointly issued the second China Academy of Sciences-WeiGao Group's second scientific research project guide. The main R&D directions include high-tech fields such as medical materials, medical consumables, medical equipment, and biomedicine.
“Current domestic hospitals use high-end medical consumables, diagnostic and therapeutic equipment, and implanted therapeutic devices and devices, which mainly rely on imports. This is one of the main factors contributing to high domestic treatment costs.†Chen Xueli, chairman of Weigao Group’s Board of Directors, told the reporter. The Weigao Group has researched and developed the above materials and machinery. After mass production, the cost of domestic products will be reduced by 50-60%."
In the investigation, the reporter found that the overall technology of China's medical devices is far from the advanced level in foreign countries. In some high-end product areas, foreign companies are in an absolute monopoly position.
“High-end medical devices such as electrocardiographs, CTs, magnetic resonances, etc. can hardly see domestic brands, and multinational companies have monopolized more than 80% of the domestic market share.†Zheng Quanlu, former vice president of the China Medical Device Industry Association, told reporters in the field of ultrasonic instruments and magnetics. In areas such as resonance equipment, the monopoly share of multinational corporations even exceeds 90%. “This is a de facto absolute monopoly. The result is a high price, and it also exacerbates the problem of the 'expensive' doctors.â€
According to statistics from the China Medical Device Industry Association, there are about 3,000 medical device manufacturers in China, but most of them are small in scale and have limited market power. Most of the high-end medical devices are based on imitation and improvement, with the exception of individual companies. .
“If we only focus on the medium and low-end markets, the path for Chinese medical device companies will only go further and narrower.†Chen Xueli said that the localization of high-end medical devices not only helps improve the overall competitiveness of China's medical devices, but also can effectively reduce the people. Medical costs.
In 2005, Weigao Group and the Dalian Institute of Chemicals of the Chinese Academy of Sciences jointly developed a recombinant protein immunoadsorption column, which was mainly used for the rejection reaction caused by hemodialysis or organ transplantation to break the monopoly of the German Fresenius company.
Previously, domestic hemodialysis patients needed more than RMB 400 per dialysis fee, and each patient needed more than RMB 60,000 per year; after WeiGao achieved localization, the cost per dialysis could drop by nearly 50%, and it could be for each year. The patient saves more than 30,000 yuan, while there are more than 2 million patients with kidney disease in China. If we use Weigao's products for treatment, it can save more than 60 billion yuan per year for kidney dialysis patients nationwide.
In recent years, the medical device industry in China has developed rapidly. However, the medical device industry is a comprehensive industry with a high concentration of technologies and involves a wide range of disciplines. The technical threshold is high. Based on the late start, the technology of the Chinese medical industry is far below the international level. To this end, the Chinese Academy of Sciences has increased the research and layout of medical devices, medical materials, and Pratt & Whitney's low-cost medical treatment methods, and has made a number of important scientific and technological achievements.
To promote the development of domestic medical equipment, medical devices, medical materials and biopharmaceutical industries, research and development of disease diagnosis and treatment methods and products with high technical level, good product quality, and cost-effective products, April 29, 2010, Chinese Academy of Sciences and Weigao Group The framework agreement for the "Chinese Academy of Sciences - Weigao Group High-Tech Research and Development Program" was signed.
According to the agreement, the development plan will annually arrange R&D expenses of 30 million yuan, of which Weigao Group will invest 15 million yuan, Shandong Province Science and Technology Agency will invest 5 million yuan on behalf of Shandong Province, Chinese Academy of Sciences will invest 5 million yuan, and the Weihai Municipal Government will invest 5 million yuan. All funds are mainly invested in the frontiers of scientific and technological development in China's medical equipment, medical equipment, medical materials, and bio-pharmaceuticals, and strive to integrate superior resources of the domestic medical device industry in basic theoretical research, applied technology research and development, product trial production, innovation platform construction, and information We will carry out all-round cooperation with personnel exchanges and other areas to jointly improve the ability of independent innovation and the market competitiveness of enterprises.
The leader of the cooperation program and head of the Shenyang Branch of the Chinese Academy of Sciences, Bao Xinhe, said: "The establishment of this plan is a new attempt by the Chinese Academy of Sciences to explore cooperation models with government and private enterprises, and promote the effective integration of science and technology with the economy and promote The scientific and technological system reform and other aspects are important examples. The successful implementation of the plan will further strengthen the promotion of research results of the Chinese Academy of Sciences and promote the rapid development of high-end medical devices and important biomedical materials in China."
"In addition to localization of high-end medical devices, we can break the monopoly of foreign companies to the market, and will also solve the problem of 'expensive medical services' to some extent." Zheng Quanlu said that foreign companies such as Medtronic, BD and Johnson & Johnson have monopolized more than 80% of domestic high-end products. The medical device market has led to high prices, and scientific research institutions need to increase support for ethnic medical device companies.
"National medical devices should go out of the competition of homogenization, accelerate independent innovation and industrial upgrading, vigorously develop high-end products, and form their own iconic products, core competitiveness and international brands," said Chen Xueli.
Oxygen Cylinder Filling System
With PSA principles, ETR Oxygen Cylinder Filling system can produce 93%±3% purity oxygen gas from compressed air directly. ETR oxygen cylinder filling system is consisted of Atlas screw air compressor, refrigerated air dryer, compressed air filter, air buffer tank, ETR Oxygen Plant, oxygen buffer tank, oxygen booster, cylinder filling station and HMI control cabinet.
Compressed air is purified through the air dryer and filters to a certain level for main plant to work with. Air buffer is incorporated for smooth supply of compressed air thus to reduce fluctuation of compressed air source. The plant produces oxygen with PSA (pressure swing adsorption) technology, which is a time proven oxygen generation method. Oxygen of desired purity at 93%±3% is delivered to oxygen buffer tank for smooth supply of product gas. Oxygen in buffer tank is maintained at 4bar pressure. With an oxygen booster, the oxygen pressure can be to 150bar and fill in cylinders.
Onsite Oxygen Cylinder Filling System
Onsite Oxygen Cylinder Filling System,Oxygen Refilling System ,Oxygen Cylinder Filling,Oxygen Refilling Machine
Hunan Eter Electronic Medical Project Stock Co., Ltd. , https://www.centralgas.be